Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization - PubMed (original) (raw)

Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization

J Weber et al. J Virol. 1996 Nov.

Abstract

Human immunodeficiency virus type 1 (HIV-1) primary isolates from four geographical locations in Thailand, Brazil, Rwanda, and Uganda, representing genetic subtypes A, B, C, D, and E, were examined for autologous and heterologous neutralization by panels of human HIV+ polyclonal plasma. In independent linked experiments in three laboratories using diverse methodologies and common reagents, no defined pattern of genetic subtype-specific neutralization was observed. Most plasma tested were broadly cross-neutralizing across two or more genetic subtypes, although the titer of neutralization varied across a wide range. We conclude that the genetic subtypes of HIV-1 are not classical neutralization serotypes.

PubMed Disclaimer

Similar articles

• Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
  Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, Wasi C. Auewarakul P, et al. Viral Immunol. 1996;9(3):175-85. doi: 10.1089/vim.1996.9.175. Viral Immunol. 1996. PMID: 8890476
• Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
  Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Kostrikis LG, et al. J Virol. 1996 Jan;70(1):445-58. doi: 10.1128/JVI.70.1.445-458.1996. J Virol. 1996. PMID: 8523557 Free PMC article.
• Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
  Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, Montefiori DC. Bures R, et al. J Virol. 2002 Mar;76(5):2233-44. doi: 10.1128/jvi.76.5.2233-2244.2002. J Virol. 2002. PMID: 11836401 Free PMC article.
• Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
  Louisirirotchanakul S, Beddows S, Cheingsong-Popov R, Shaffer N, Mastro TD, Auewarakul P, Likanonsakul S, Wasi C, Weber J. Louisirirotchanakul S, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):315-20. doi: 10.1097/00042560-199812010-00001. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9833739
• Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
  Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC. Simek MD, et al. J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13. J Virol. 2009. PMID: 19439467 Free PMC article.

Cited by

• Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.
  Del Mauro D, Matteucci D, Giannecchini S, Maggi F, Pistello M, Bendinelli M. Del Mauro D, et al. J Virol. 1998 Mar;72(3):2199-207. doi: 10.1128/JVI.72.3.2199-2207.1998. J Virol. 1998. PMID: 9499077 Free PMC article.
• Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.
  Björndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyö EM. Björndal A, et al. J Virol. 1997 Oct;71(10):7478-87. doi: 10.1128/JVI.71.10.7478-7487.1997. J Virol. 1997. PMID: 9311827 Free PMC article.
• HIV-1 prophylactic vaccines: state of the art.
  Lelièvre JD, Lévy Y. Lelièvre JD, et al. J Virus Erad. 2016 Jan 1;2(1):5-11. doi: 10.1016/S2055-6640(20)30695-6. J Virus Erad. 2016. PMID: 27482428 Free PMC article. Review.
• Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.
  Moore JP, Parren PW, Burton DR. Moore JP, et al. J Virol. 2001 Jul;75(13):5721-9. doi: 10.1128/JVI.75.13.5721-5729.2001. J Virol. 2001. PMID: 11390574 Free PMC article. Review. No abstract available.

References

1. 1. Science. 1993 Nov 19;262(5137):1257-61 - PubMed
2. 1. AIDS. 1993 Jun;7(6):769-80 - PubMed
3. 1. J Virol. 1994 Mar;68(3):1342-9 - PubMed
4. 1. J Infect Dis. 1995 Feb;171(2):305-11 - PubMed
5. 1. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1359-68 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information